**Adaptive Biotechnologies (ADPT)** shares jumped 9.7% in the latest trading session, closing at $18.73. This increase is notable, particularly given the stock’s overall rise of 30% over the past four weeks, driven by higher trading volumes. The company reported strong first-quarter 2026 results, with expectations of a quarterly loss of $0.13 per share, a 23.5% improvement year-over-year, and projected revenues of $67.24 million, up 14.2% from last year.
The consensus earnings per share estimate for Adaptive Biotechnologies has risen 3.6% in the past month, indicating a trend that may lead to further price appreciation. The company is focused on immune-profiling diagnostics and has seen growing investor confidence in its lead commercial product, clonoSEQ.
In comparison, **Prothena (PRTA)** shares rose 4.4% to $8.26, although the stock has declined 17.6% over the past month. Prothena’s consensus EPS estimate remains unchanged at -$0.39, representing a 79% change from the previous year’s results.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
